The objective is to investigate the role of clinically significant antiphospholipid antibodies (aPL) in a cohort of systemic lupus erythematosus (SLE) patients. All SLE patients followed for at least 5 years and with available aPL profile at the beginning of the follow-up in our center were studied. Clinically significant aPL were defined as: positive lupus anticoagulant test, anti-cardiolipin and/or antiβ2Glycoprotein I IgG/IgM >99 th percentile on two or more occasions at least 12 weeks apart. Patients with and without clinically significant aPL were compared by univariate (Chi square or Fisher's exact test for categorical variables and Student's t or Mann-Whitney test for continuous variables) and multivariate analysis (logistic regression analysis). P values <0.05 were considered significant. Among 317 SLE patients studied, 117 (37%) had a clinically significant aPL profile at baseline. Such patients showed at univariate analysis an increased prevalence of deep venous thrombosis, pulmonary embolism, cardiac valvular disease, cognitive dysfunction and antiphospholipid syndrome (APS), but a reduced prevalence of acute cutaneous lupus and anti-extractable nuclear antigens (ENA) when compared with patients without clinically significant aPL. Multivariate analysis confirmed the association between clinically significant aPL and reduced risk of acute cutaneous lupus [p=0.003, odds ratio (OR) 0.43] and ENA positivity (p<0.001, OR 0.37), with increased risk of cardiac valvular disease (p=0.024, OR 3.1) and APS (p<0.0001, OR 51.12). Triple positivity was the most frequent profile and was significantly associated to APS (p<0.0001, OR 28.43). Our study showed that one third of SLE patients had clinically significant aPL, and that this is associated with an increased risk, especially for triple positive, of APS, and to a different clinical and serological pattern of disease even in the absence of APS.
n INTRODUCTION S ystemic lupus erythematosus (SLE) is a systemic autoimmune disease with a heterogeneous spectrum of possible clinical and serological manifestations. Patients with SLE can produce a great variety of autoantibodies including antinuclear antibodies, anti-extractable nuclear antigen antibodies (ENA), anti-double stranded DNA antibodies (dsDNA), but also the so called antiphospholipid antibodies (aPL) such as anti-cardiolipin antibodies (aCL), anti-β2Glycoprotein I antibodies (aβ2GPI) or lupus anticoagulant (LA) (1) . Antiphospholipid antibodies are the hallmark of antiphospholipid syndrome (APS), a condition that is characterized by pregnancy morbidity and/or thrombosis and that can be isolated (primary APS) or associated with other autoimmune diseases, in particular SLE (2) . Antiphospholipid antibodies have been described in 20-40% of SLE patients, with 50-70% of patients with SLE and aPL showing the clinical features of APS after 20 years of follow-up (3). We recently described in a multiethnic cohort of SLE patients how the presence of clinically significant (persistent medium to high titer) aPL is a risk factor for irreversible organ damage accrual during a fifteenyear follow-up (4) . Anyway the collabora- th percentile, defined as ≥20 G or M antiphospholipid units), LA by coagulation assay. For aβ2GPI in patients followed before the test was available, the first determinations during the follow-up were used. Categorical variables were reported as proportion and/or percentage. Continuous variables were reported as mean (±stan-dard deviation, SD) or median (range) value. For the univariate analysis the characteristics of patients with and without clinically significant aPL, and of patients with and without single, double and triple aPL positivity were compared by the Chi square or Fisher's exact test for categorical variables and by Student's t test or Mann-Whitney-Wilcoxon test for continuous variables as appropriate. Variables that were found to be significantly associated with clinically significant aPL or triple aPL positivity at univariate analysis and that were considered relevant were included in the multivariate analysis by logistic regression analysis (StatView program version 5.1). P values <0.05 were considered significant. When significant, odds ratio (OR) with 95% confidence interval (95%CI) was indicated. This study was performed according to the principles of the Declaration of Helsinki and the registry was approved by the local Ethics Committee.
n RESULTS Three hundred and seventeen SLE patients (95% female, 96% Caucasian), prospectively followed in our Unit from 1972 to Tables I  and II . Patients with clinically significant aPL showed a distinct clinical and serological profile. In particular, they had an increased prevalence of deep venous thrombosis (DVT), pulmonary embolism (PE), cardiac valvular disease, cognitive dysfunction and APS, but a reduced prevalence of acute cutaneous lupus (ACLE) compared to patients without clinically significant aPL. From a serological point of view, they also had a reduced prevalence of ENA, in particular anti-Ro/SSA, antiSmith and anti-U1RNP antibodies. Multivariate analysis by logistic regression showed an association between clinically significant aPL and a reduced risk of ACLE (p=0.003, OR 0.43, 95%CI: 0.43-0. 24 
n DISCUSSION AND CONCLUSIONS
This study was focused on a cohort of SLE patients with complete aPL testing at baseline, followed for a median follow-up of 15 years. In this cohort, we observed that around one-third of patients had clinically significant aPL and that such autoantibody positivity was associated with APS, but also with a different clinical and serological profile even in the absence of APS. The prevalence of clinically significant aPL in this monocentric cohort (37%) is similar to that we recently described (33%) in a multicentric cohort of SLE, where we demonstrated an association with an increased risk of damage accrual during a 15-year follow-up (4). The prevalence of APS in our SLE cohort (19%) is consistent with that previously described in the literature (20%) (3). The interest of our work was to identify any difference in SLE expression among patients with and without clinically significant aPL. Antiphospholipid antibodies are well known to be associated with thrombotic events and adverse pregnancy outcome (2), and these events have been demonstrated to occur more frequently in SLE patients with aPL (9, 10). We were not able to document the pregnancy history of our patients as the information was not included in the registry. In any case, patients with clinically significant aPL had, as expected, an Clinically significant aPL in SLE original paper increased prevalence of venous thrombosis (11) . On the other hand, we did not observe an association with arterial events, such as myocardial infarction and stroke. This observation could be explained by the fact that other risk factors, such as traditional cardiovascular risk factors (hypercholesterolemia, hypertension, diabetes and metabolic syndrome) have been shown to be more prevalent in SLE patients and to participate, together with the inflammatory burden associated with disease activity, in the pathogenesis of premature atherosclerosis and arterial ischemic events (12) (13) (14) .
Other clinical features have been associated with the presence of aPL and described in the clinical picture of systemic manifestations of APS (15) . In our study, we confirmed the association with valvular heart disease, one of the possible manifestations of APS, which has been shown to be more prevalent in SLE patients with aPL compared to those without these autoantibodies (16, 17) . We also found, as already described, that SLE with clinically significant aPL had more frequently cognitive dysfunction, even if a standardized cognitive examination was not routinely performed in our cohort, possibly limiting the diagnosis to more evident and severe cases (18, 19) . No association was found with other manifestations classically related to aPL, such as thrombocytopenia and hemolytic anemia, but other autoantibodies such as antiplatelet antibodies (directed against platelet membrane glycoproteins) and anti-red blood cell antibodies (mainly directed against Rh molecules) are known to be involved in the pathogenesis of these manifestations (20, 21) . The prevalence of pulmonary hypertension in our cohort was probably too low (1%) to study any association with aPL (22, 23) . The lack of association between venous thrombotic events, cognitive dysfunction and clinically significant aPL at multivariate analysis possibly suggests that these manifestations are not independent, but belong to the APS spectrum. Acute cutaneous lupus is known to be associated with ENA, in particular anti-Ro and Sm (24). We were not expecting the inverse association between clinically significant aPL and ACLE or ENA, but we concluded that this observation reflects the fact that SLE patients with clinically significant aPL showed a different disease phenotype, possibly influenced by a different genetic background (25, 26) . Triple aPL positivity was the most frequent original paper scenario among patients with clinically significant aPL. Such a profile, which is known to be a strong predictor of thrombotic events (27) and pregnancy morbidity (28) , was the only one that showed an independent association with APS. The limitations of our study are the retrospective design and the lack of information about pregnancy outcome and renal non-glomerular disease. Its strengths are the long follow-up and the use of recommended aPL testing in a single referral laboratory.
In conclusion, our study showed that SLE patients with clinically significant aPL have an increased risk, especially if triple positive, of developing APS, but also show a different clinical and serological profile even in the absence of APS. 
